Inhibrx
INBX
86 hedge funds and large institutions have $137M invested in Inhibrx in 2024 Q2 according to their latest regulatory filings, with 86 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
66.65% more ownership
Funds ownership: 0% → 66.65% (+67%)
44% more call options, than puts
Call options by funds: $2.23M | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$27.9M |
| 2 |
PA
Perceptive Advisors
New York
|
+$16.6M |
| 3 |
BlackRock
New York
|
+$10.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.47M |
| 5 |
Walleye Capital
New York
|
+$7.42M |
Top Sellers
INBX Hedge Fund Activity: Q2 2024 in Review
86 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q2 2024, worth a combined $137M.
Buyers outnumbered sellers: 86 funds opened new INBX positions and 0 closed out — a net gain of 86 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $27.9M.
- 86 institutional investors held Inhibrx (INBX) as of Q2 2024, up from 0 in Q1 2024.
- Funds reported $137M of Inhibrx stock for Q2 2024.
- 86 funds opened new Inhibrx positions in Q2 2024 and 0 closed out, a net change of +86 holders.
- The largest Inhibrx buyer in Q2 2024 was Viking Global Investors, an estimated $27.9M added.
Based on aggregated 13F filings for Q2 2024.